166 related articles for article (PubMed ID: 28736738)
1. Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes.
Nyman JS; Kalaitzoglou E; Clay Bunn R; Uppuganti S; Thrailkill KM; Fowlkes JL
Bone Rep; 2017 Dec; 7():1-8. PubMed ID: 28736738
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Inhibition of Myostatin With a Myostatin Antibody Improves the Skeletal Muscle and Bone Phenotype of Male Insulin-Deficient Diabetic Mice.
Bunn RC; Adatorwovor R; Smith RR; Ray PD; Fields SE; Keeble AR; Fry CS; Uppuganti S; Nyman JS; Fowlkes JL; Kalaitzoglou E
JBMR Plus; 2023 Nov; 7(11):e10833. PubMed ID: 38025035
[TBL] [Abstract][Full Text] [Related]
3. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525
[TBL] [Abstract][Full Text] [Related]
4. Effects of continuous subcutaneous insulin infusion on the microstructures, mechanical properties and bone mineral compositions of lumbar spines in type 2 diabetic rats.
Hu X; Gong H; Hou A; Wu X; Shi P; Zhang Y
BMC Musculoskelet Disord; 2022 May; 23(1):511. PubMed ID: 35637472
[TBL] [Abstract][Full Text] [Related]
5. Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age.
Creecy A; Uppuganti S; Unal M; Clay Bunn R; Voziyan P; Nyman JS
Bone; 2018 May; 110():204-214. PubMed ID: 29438824
[TBL] [Abstract][Full Text] [Related]
6. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
[TBL] [Abstract][Full Text] [Related]
7. Use of continuous subcutaneous insulin infusion versus multiple daily injections in emerging adults with type 1 diabetes is associated with better clinical engagement but not glycaemic control.
Chai TYL; Farrell K; Holmes-Walker DJ
Intern Med J; 2023 Feb; 53(2):255-261. PubMed ID: 34561942
[TBL] [Abstract][Full Text] [Related]
8. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
[TBL] [Abstract][Full Text] [Related]
9. Experiences and real life management of insulin pump therapy in adults with type 1 diabetes.
Quirós C; Jansà M; Viñals C; Giménez M; Roca D; Escarrabill J; Garcia F; Pérez S; Conget I
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):117-123. PubMed ID: 30076125
[TBL] [Abstract][Full Text] [Related]
10. Both spontaneous Ins2(+/-) and streptozotocin-induced type I diabetes cause bone loss in young mice.
Coe LM; Zhang J; McCabe LR
J Cell Physiol; 2013 Apr; 228(4):689-95. PubMed ID: 22886636
[TBL] [Abstract][Full Text] [Related]
11. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Effects of Continuous Subcutaneous Insulin Infusion on Glucose Control and Microvascular Complications in Patients With Type 1 Diabetes.
Marchand L; Kawasaki-Ogita Y; Place J; Fayolle C; Lauton D; Boulet F; Farret A; Renard E
J Diabetes Sci Technol; 2017 Sep; 11(5):924-929. PubMed ID: 28303725
[TBL] [Abstract][Full Text] [Related]
13. [Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus].
Hasselmann C; Bonnemaison E; Faure N; Mercat I; Bouillo Pépin-Donat M; Magontier N; Chantepie A; Labarthe F
Arch Pediatr; 2012 Jun; 19(6):593-8. PubMed ID: 22584198
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study.
Silva VB; Fonseca L; Duarte DB; Puga FM; Assuncao G; Garrido S; Teixeira S; Vilaverde J; Cardoso MH
Endocr Regul; 2023 Jan; 57(1):144-151. PubMed ID: 37561831
[No Abstract] [Full Text] [Related]
15. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M
Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639
[TBL] [Abstract][Full Text] [Related]
16. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
17. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Continuous Subcutaneous Insulin Infusion on Parental Quality of Life and Glycemic Control Among Children With T1D: Meta-Analysis.
Li AY; So WK; Leung DY
Worldviews Evid Based Nurs; 2018 Oct; 15(5):394-400. PubMed ID: 30033649
[TBL] [Abstract][Full Text] [Related]
19. Long-term body weight trajectories and metabolic control in type 1 diabetes patients on insulin pump or multiple daily injections: A 10-year retrospective controlled study.
Alderisio A; Bozzetto L; Franco L; Riccardi G; Rivellese AA; Annuzzi G
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1110-1117. PubMed ID: 31371264
[TBL] [Abstract][Full Text] [Related]
20. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
Pala L; Dicembrini I; Mannucci E
Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
